Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A reporting on holdings of Teladoc Health Inc. The filing states amount beneficially owned: 0 and percent of class: 0%, reflecting an internal realignment where certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The filing lists Vanguard's address and certifies that no other single person holds more than 5% of the class. The form is signed by Ashley Grim on 03/27/2026.
Teladoc Health, Inc. President, U.S. Group Health, Kelly Bliss reported compensation-related equity activity involving performance stock units tied to common stock. On 2026-02-27, she was granted 15,596 performance stock units, each representing a contingent right to receive one share of TDOC common stock.
The award size was determined using metrics based on Teladoc’s 2025 financial results, and the units vest one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments. The filing also records the exercise or conversion of 5,198 performance stock units into common stock and amends a prior Form 4 to correct the originally reported number of units awarded.
Teladoc Health, Inc. reported insider activity by CEO Charles DiVita III involving equity awards, vesting, and related tax sales. On March 10, 2026, restricted stock units and performance stock units converted one-for-one into a total of 64,653 shares of common stock. He was also awarded 43,703 performance stock units, with vesting tied to the company’s 2025 financial results and a schedule that began March 10, 2026. On March 11, 2026, 27,731 shares of common stock were sold at $5.49 per share to cover tax withholding obligations related to these vestings. After these transactions, DiVita directly owned 364,784 shares of Teladoc common stock.
TDOC affiliate files Form 144 reporting proposed and recent sales of common stock.
The filing lists 27,731 restricted shares tied to vesting on 03/10/2026 as securities to be sold. It also records dispositions by Charles Divita of 17,138 shares on 12/11/2025 and 50,145 shares on 03/02/2026.
Teladoc Health’s chief legal officer Adam C. Vandervoort reported a mix of equity awards, vesting and a related share sale. On March 2, he sold 27,083 shares of common stock at $5.117 per share to cover tax withholding obligations tied to recently vesting awards. Following this sale, he directly owned 103,239 common shares.
On March 1, he received a grant of 181,661 restricted stock units, each representing a contingent right to one Teladoc common share. Around February 27, multiple restricted stock unit and performance stock unit awards converted into common stock on a one-for-one basis, and he also earned 5,107 performance stock units based on metrics related to the company’s 2025 financial results.
Teladoc Health, Inc. director and CEO Charles DiVita III reported a mix of stock sales, grants, and conversions. He sold 50,145 shares of common stock at $5.117 per share in an open-market transaction, with a footnote stating the sale was to cover tax withholding obligations from vesting equity awards. After this sale, he directly held 327,862 common shares.
DiVita also acquired 692,041 restricted stock units and 23,591 performance stock units, each representing a contingent right to receive one share of Teladoc common stock on a one-for-one basis, subject to vesting schedules tied in part to 2025 financial metrics. Additional exercises and conversions of 169,107 and 7,864 derivative units into common shares were reported, reflecting ongoing equity-based compensation activity.
Teladoc Health, Inc.’s Chief Accounting Officer, Joseph Ronald Catapano, reported a mix of stock sales, vesting, and new equity awards. He sold 1,333 shares of common stock at $5.117 per share, with a footnote stating the sale was made to cover tax withholding tied to vesting of his restricted and performance stock units.
On the equity award side, he received a grant of 15,000 restricted stock units, each representing a contingent right to one share of Teladoc common stock, and 465 performance stock units earned based on 2025 financial metrics, also convertible one-for-one into common shares. Footnotes state these awards generally vest one-third on the first anniversary of the grant or earning date, with the remainder vesting in eight substantially equal quarterly installments thereafter. Following these transactions, he directly owned 8,841 shares of common stock, plus outstanding RSU and PSU awards.
Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, reported a mix of stock sales and equity awards. Bliss sold 26,647 shares of common stock in an open-market transaction at $5.117 per share to cover tax withholding obligations related to vesting equity awards, and held 84,747 common shares afterward.
On March 1, 2026, Bliss received a grant of 181,661 restricted stock units, each representing a contingent right to one Teladoc share, generally vesting one-third on the first anniversary of the grant date with the balance in eight quarterly installments. Around February 27, 2026, multiple restricted stock unit and performance stock unit awards were exercised or earned, including 27,458 performance stock units determined using metrics tied to Teladoc’s 2025 financial results, all converting to common stock on a one-for-one basis.
Fernando Madeira Rodrigues reported a proposed sale of 25,086 common shares tied to restricted stock vesting on 03/01/2026. The filing lists the shares as to be sold through Fidelity Brokerage Services LLC on the NYSE.
It also discloses prior sales in the past three months: 4,209 shares sold on 12/03/2025 for $31,483.32 and 16,314 shares sold on 03/02/2026 for $83,473.84.
Teladoc Health executive Carlos Nueno reported multiple equity transactions involving Teladoc Health, Inc. common stock and equity awards. On March 2, 2026, he sold 20,165 shares of common stock in an open‑market transaction at $5.117 per share, with a footnote stating the sale was to cover tax withholding obligations from vesting awards.
On March 1, 2026, he received a grant of 173,010 restricted stock units with each unit representing a contingent right to one Teladoc share. On February 27, 2026, several blocks of restricted stock units and performance stock units converted into common stock on a one‑for‑one basis, increasing his shareholdings. After these transactions, he directly owned 50,595 common shares.